Evidence map›Paper›PMID 39890823›Full record

ArticleScientific reports2025

Prognostic impact of moderate to severe anemia associated with renal dysfunction in patients with heart failure.

Eri Noda, Shouji Matsushima, Toru Hashimoto, Yoshitomo Tsutsui, Kayo Misumi, Nobuyuki Enzan, Keimei Yoshida, Keisuke Shinohara, Takeo Fujino, Shunsuke Katsuki and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eri NodaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Shouji MatsushimaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan. matsushima.shoji.056@m.kyushu-u.ac.jp.
Toru HashimotoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Yoshitomo TsutsuiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Kayo MisumiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Nobuyuki EnzanDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Keimei YoshidaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Keisuke ShinoharaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Takeo FujinoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Shunsuke KatsukiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Takafumi SakamotoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Kazuya HosokawaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Shintaro KinugawaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Kohtaro AbeDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Moderate/severe anemia [hemoglobin (Hb) < 10 g/dL] is recommended to be treated in patients with renal anemia. However, the optimal therapeutic target for Hb levels in patients with heart failure (HF) is unknown. This study aimed to investigate the impact of severity of anemia, especially moderate/severe anemia, associated with renal dysfunction (RD: eGFR < 60 mL/min/1.73 m

Indexed as

AnemiaHeart FailureAgedAged, 80 and overFemaleGlomerular Filtration RateHemoglobinsHospitalizationHumansJapanMaleMiddle AgedPrognosisRegistriesSeverity of Illness IndexHemoglobinsAnemiaHeart failureRenal dysfunction

Identifiers

PMID39890823
PMCPMC11785720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.